Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. BPMC Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Blueprint Medicines (BPMC)

Market Price (9/4/2025): $129.5 | Market Cap: $8.3 Bil
Sector: Health Care | Industry: Biotechnology

Blueprint Medicines (BPMC)

Market Price (9/4/2025): $129.5
Market Cap: $8.3 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 99%		  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -174 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.2%
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 99%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -174 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31%
2 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.2%

Market Valuation

 9/4/252024202320222021
Share Price CYE$129.50$87.22$92.24$43.81$107.11
Market Cap CYE ($ Bil)8.35.55.62.66.3
Total Debt ($ Bil)0.50.50.30.20.1
Total Cash ($ Bil)0.60.60.70.90.5
Enterprise Value ($ Bil)8.26.05.92.86.4
Valuation Ratios     
P/S TTM14.810.822.412.834.8
P/EBIT TTM-100.81862.9-12.3-4.9-9.9
P/E TTM-53.3-81.7-11.0-4.7-9.7
Sector Ratios     
P/S TTM (Sector)3.84.14.54.56.7
P/EBIT TTM (Sector)4.30.4-1.9-1.2-0.4
P/E TTM (Sector)-1.8-2.2-3.4-2.2-2.3
 9/4/2520242023
Share Price CYE$129.50$87.22$92.24
Market Cap CYE ($ Bil)8.35.55.6
Total Debt ($ Bil)0.50.50.3
Total Cash ($ Bil)0.60.60.7
Enterprise Value ($ Bil)8.26.05.9
Valuation Ratios   
P/S TTM14.810.822.4
P/EBIT TTM-100.81862.9-12.3
P/E TTM-53.3-81.7-11.0
Sector Ratios   
P/S TTM (Sector)3.84.14.5
P/EBIT TTM (Sector)4.30.4-1.9
P/E TTM (Sector)-1.8-2.2-3.4

Market Cap Chart

Business Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
BPMC Return40%-4%-59%111%-5%48%-100%
Peers Return11%18%23%15%2%8%103%
S&P 500 Return16%27%-19%24%23%10%100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Better Bets than Blueprint Medicines (BPMC)

 BPMCBetter Performance than BPMC
MetricValueIndustry (Biotechnology)
Rev Chg LTM99.2%MDGL (3422.0%), CYTK (2635.7%), KRYS (116.1%), ARWR (2816.2%), TARS (254.5%)
Rev Chg 3Y Avg43.2%BBIO (1225.0%), RYTM (137.5%), LEGN (107.2%), AXSM (699.5%), CYTK (824.6%)
Op Mgn LTM-31.0%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-25.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-26.8%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-1.9%ABBV (4.0%), AMGN (7.5%), GILD (7.3%), VRTX (3.5%), REGN (7.6%)
 BPMCBetter Performance than BPMC
MetricValueAll Other Sectors
Rev Chg LTM99.2%ALAB (163.8%), SW (163.8%), CG (133.3%), NLY (375.8%), QXO (3313.1%)
Rev Chg 3Y Avg43.2%NVDA (92.0%), RCL (65.4%), APO (129.8%), CCL (81.1%), LVS (48.7%)
Op Mgn LTM-31.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-25.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-26.8%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-1.9%NVDA (2.1%), MSFT (3.4%), AAPL (3.3%), GOOGL (4.9%), AMZN (2.9%)

Latest Trefis Analyses

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1EAFGrafTech International804.0%-47.2%
2RLMDRelmada Therapeutics122.3%182.7%
3XELAExela Technologies109.6%-95.5%
4PSNYWPolestar Automotive UK96.2%141.5%
5TKCMToken Communities82.8%-64.7%
6PHJMFPT Hanjaya Mandala Sampoerna66.7%34.8%
7ANGGFAngang Steel61.2%25.0%
8DTNOFDNO49.5%141.9%
9BWBabcock & Wilcox Enterprises48.5%54.9%
10MDBMongoDB46.0%34.4%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1COSGGrand Gallery-100.0%�
2PTLKFPT Lippo Karawaci-95.2%-94.7%
3NXTTNext Technology-74.5%-89.4%
4SCGYScientific Energy-72.7%-26.9%
5MGAWFMegaworld-71.0%-71.0%
6TTOOT2 Biosystems-67.7%-99.0%
7PTTMFPT Timah-62.8%-83.1%
8PIGEFPigeon-62.4%-62.4%
9NEGGNewegg Commerce-53.8%290.6%
10PTJSFPT Jasa Marga-50.9%-50.9%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1MMEXMMEX Resources∞%-50.0%
2TAWNFThai Airways International3674.5%3400.0%
3NOKPFNok Airlines2400.0%81.8%
4AYRWFAyr Wellness509.5%-94.6%
5XELAExela Technologies379.0%-95.5%
6SRNESorrento Therapeutics233.3%900.0%
7PGENPrecigen169.9%324.1%
8TLSTelos154.7%89.2%
9SATSEchoStar142.7%179.1%
10RLMDRelmada Therapeutics139.0%182.7%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1COSGGrand Gallery-100.0%�
2PTLKFPT Lippo Karawaci-95.2%-94.7%
3TTOOT2 Biosystems-94.8%-99.0%
4NXTTNext Technology-86.5%-89.4%
5OTRKOntrak-78.2%-96.6%
6SCGYScientific Energy-72.7%-26.9%
7PPCBPropanc Biopharma-72.1%-79.1%
8MGAWFMegaworld-71.0%-71.0%
9PTTMFPT Timah-62.8%-83.1%
10PIGEFPigeon-62.4%-62.4%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1EAFGrafTech International804.0%-47.2%
2RLMDRelmada Therapeutics122.3%182.7%
3XELAExela Technologies109.6%-95.5%
4PSNYWPolestar Automotive UK96.2%141.5%
5TKCMToken Communities82.8%-64.7%
6PHJMFPT Hanjaya Mandala Sampoerna66.7%34.8%
7ANGGFAngang Steel61.2%25.0%
8DTNOFDNO49.5%141.9%
9BWBabcock & Wilcox Enterprises48.5%54.9%
10MDBMongoDB46.0%34.4%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1COSGGrand Gallery-100.0%�
2PTLKFPT Lippo Karawaci-95.2%-94.7%
3NXTTNext Technology-74.5%-89.4%
4SCGYScientific Energy-72.7%-26.9%
5MGAWFMegaworld-71.0%-71.0%
6TTOOT2 Biosystems-67.7%-99.0%
7PTTMFPT Timah-62.8%-83.1%
8PIGEFPigeon-62.4%-62.4%
9NEGGNewegg Commerce-53.8%290.6%
10PTJSFPT Jasa Marga-50.9%-50.9%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Blueprint Medicines

Financials

BPMCVRTXABBVAMGNGILDREGNMedian
NameBlueprin.Vertex P.AbbVie Amgen Gilead S.Regenero. 
Mkt Price-401.00211.92286.92112.71577.90286.92
Mkt Cap8.3102.9374.7154.4140.360.7121.6
Rev LTM56211,41958,32834,91728,86214,21421,538
Op Inc LTM-174-19913,6958,19210,7973,8416,016
FCF LTM-1513,50018,23910,6059,3693,5566,463
FCF 3Y Avg-3611,98420,2738,5908,3973,2485,823
CFO LTM-1463,84619,28312,0139,8684,7447,306
CFO 3Y Avg-3512,32421,1549,7538,9494,5186,733

Growth & Margins

BPMCVRTXABBVAMGNGILDREGNMedian
NameBlueprin.Vertex P.AbbVie Amgen Gilead S.Regenero. 
Rev Chg LTM99.2%10.5%6.1%12.9%3.8%5.4%8.3%
Rev Chg 3Y Avg43.2%11.0%0.6%10.0%1.6%0.3%5.8%
Rev Chg Q55.5%12.1%6.6%9.4%1.8%3.6%8.0%
QoQ Delta Rev Chg LTM10.5%2.9%1.7%2.3%0.4%0.9%2.0%
Op Mgn LTM-31.0%-1.7%23.5%23.5%37.4%27.0%23.5%
Op Mgn 3Y Avg-151.5%26.5%27.2%26.4%39.2%30.1%26.8%
QoQ Delta Op Mgn LTM10.7%2.0%1.0%1.6%-0.0%-0.2%1.3%
CFO/Rev LTM-25.9%33.7%33.1%34.4%34.2%33.4%33.5%
CFO/Rev 3Y Avg-137.9%22.5%37.5%32.0%31.9%33.6%31.9%
FCF/Rev LTM-26.8%30.6%31.3%30.4%32.5%25.0%30.5%
FCF/Rev 3Y Avg-141.7%19.2%36.0%28.2%30.0%24.1%26.1%

Valuation

BPMCVRTXABBVAMGNGILDREGNMedian
NameBlueprin.Vertex P.AbbVie Amgen Gilead S.Regenero. 
Mkt Cap8.3102.9374.7154.4140.360.7121.6
P/S14.89.06.44.44.94.35.6
P/EBIT-100.823.463.614.917.112.416.0
P/E-53.328.399.623.322.213.622.8
P/CFO-57.026.819.412.814.212.813.5
Total Yield-1.9%3.5%4.0%7.5%7.3%7.6%5.7%
Dividend Yield0.0%0.0%3.0%3.2%2.8%0.3%1.6%
FCF Yield 3Y Avg-7.2%2.1%7.3%6.2%8.0%4.4%5.3%
D/E0.10.00.20.40.20.00.1
Net D/E-0.0-0.00.20.30.1-0.10.1

Returns

BPMCVRTXABBVAMGNGILDREGNMedian
NameBlueprin.Vertex P.AbbVie Amgen Gilead S.Regenero. 
1M Rtn--13.2%8.6%-2.6%-0.4%3.6%-0.4%
3M Rtn--10.2%14.2%-0.1%3.8%18.6%3.8%
6M Rtn--17.5%3.8%-6.5%-0.4%-14.2%-6.5%
12M Rtn--19.1%11.8%-11.2%47.3%-51.0%-11.2%
3Y Rtn-42.7%74.1%30.3%97.4%-0.0%42.7%
1M Excs Rtn--16.1%5.7%-5.4%-3.3%0.7%-3.3%
3M Excs Rtn--18.1%6.2%-7.8%-3.9%9.8%-3.9%
6M Excs Rtn--26.7%-7.7%-15.8%-11.1%-25.0%-15.8%
12M Excs Rtn--32.8%-2.4%-24.7%33.4%-66.3%-24.7%
3Y Excs Rtn--15.1%17.5%-24.3%45.4%-56.7%-15.1%

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date5/1/20252/13/202510/30/20248/1/20245/2/20242/15/202410/26/20238/2/20235/4/20232/16/202311/1/20228/2/2022
Key Financials Quarterly            
Total Revenue1491461281389672575863396637
Ebitda24-27-33-29109-94-118-117-114-138-119-155
Operating Income-41-41-49-43-79-105-127-127-123-148-123-155
Net Income0-50-56-5089-111-134-133-130-159-133-160
EPS0.01-0.79-0.89-0.801.45-1.82-2.20-2.19-2.15-2.65-2.23-2.68
Key Financials TTM            
Total Revenue TTM562509434363282249216226205204272230
Ebitda TTM-6619-48-132-220-443-487-488-526-514-685-678
Operating Income TTM-174-212-276-354-438-482-525-520-549-529-692-683
Net Income TTM-156-67-128-205-288-507-555-554-581-558-718-702
Growth Rates Quarterly            
Total Revenue Growth55.5%103.4%126.6%140.0%51.9%85.5%-14.3%57.5%0.9%-63.8%172.8%33.9%
EBITDA Growth-78.4%71.3%71.6%74.9%196.1%31.8%1.5%24.4%-12.6%55.4%-6.3%-45.1%
Operating Income Growth47.9%60.8%61.5%66.0%35.9%28.9%-3.7%18.5%-19.9%52.5%-7.7%-43.3%
Net Income Growth-99.4%55.0%57.9%62.4%168.8%30.1%-0.4%16.9%-22.2%50.2%-13.6%-47.3%
Margins Quarterly            
EBITDA Margin15.8%-18.5%-26.0%-21.3%113.6%-131.1%-207.7%-203.7%-179.6%-356.4%-180.8%-424.4%
Operating Income Margin-27.5%-28.2%-38.2%-31.2%-82.0%-146.1%-224.9%-220.2%-194.2%-381.4%-185.8%-425.5%
Net Income Margin0.3%-34.1%-43.9%-36.2%92.7%-154.1%-236.4%-230.7%-204.7%-409.1%-201.8%-437.0%
Cash & Debt            
Total Cash5766157347646487117137238229451,137853
Total Debt467469471475330332334238240242244108
Net Debt / (Cash)-110-146-263-289-318-378-379-484-582-703-893-746
Cash Flows Quarterly            
FCF from Operations-54-29-14-48-102-79-104-130-123-121-130-118
Cash Flows TTM            
FCF from Operations TTM-146-193-242-333-415-437-479-505-493-502-395-361
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-2.4%-6.4%-8.1%-7.4%-14.0%-20.1%-24.8%-26.4%-27.4%-36.0%-34.5%-40.3%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-6.6%-8.3%-11.5%-15.2%-19.5%-23.0%-25.6%-27.1%-30.6%-32.1%-48.7%-44.3%

Price Behavior

BPMC Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta�0.010.520.670.811.00
Up Beta�-0.040.040.300.410.52
Down Beta�0.000.090.690.901.14
Up Capture0%8%132%139%140%202%
Bmk +ve Days10223571142415
Stock +ve Days051441103362
Down Capture-0%0%-1%93%105%104%
Bmk -ve Days11192754106334
Stock -ve Days041551111352

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/1/202510.9%11.5%13.2%
2/13/2025-8.1%-8.9%-13.5%
10/30/20247.0%17.0%14.0%
8/1/2024-7.4%-16.1%-13.6%
5/2/202412.8%14.7%11.3%
2/15/202414.0%12.0%17.8%
10/26/202325.6%36.3%55.7%
8/2/2023-15.3%-26.9%-23.1%
...
SUMMARY STATS   
# Positive171415
# Negative81110
Median Positive7.2%6.8%12.9%
Median Negative-7.7%-13.2%-13.5%
Max Positive25.6%40.5%55.7%
Max Negative-15.3%-26.9%-24.5%

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Carter Percy H.CHIEF SCIENTIFIC OFFICER6052025Sell127.8824130,8197,241,077Form
1Rossi ChristinaCHIEF OPERATING OFFICER5212025Sell100.1480480,5136,628,066Form
2Rossi ChristinaCHIEF OPERATING OFFICER5072025Sell100.9760761,2896,932,499Form
3Haviland KateCHIEF EXECUTIVE OFFICER4032025Sell85.4760051,28214,344,174Form
4Rossi ChristinaCHIEF OPERATING OFFICER3262025Sell95.022,274216,0756,581,655Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.